• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
Methadone - A Potted Guide

Methadone - A Potted Guide



An introductory guide to methadone as a treatment for opiate dependence. Developed by a substance misuse practitioner and registered nurse working with a community drug team.

An introductory guide to methadone as a treatment for opiate dependence. Developed by a substance misuse practitioner and registered nurse working with a community drug team.



Total Views
Views on SlideShare
Embed Views



0 Embeds 0

No embeds


Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
Post Comment
Edit your comment

    Methadone - A Potted Guide Methadone - A Potted Guide Presentation Transcript

    • Methadone A Potted Guide By Paul Molyneux
    • A Short History• During World War II the supply of opium was cut off from Germany. As a result, painkilling morphine became a medicine in short supply.• German chemist set about making a synthetic alternative. They developed a compound that acted as an opioid receptor agonist that successfully relieved pain.• That compound was methadone, however it was originally named dolophine (Hanson et al. 2009).• Methadone as a treatment for opiate dependence was developed in the 1960s as a medical response to the post-World War II heroin epidemic in New York City (Joseph et al. 2000). Paul Molyneux
    • Why Methadone?• In the UK the treatment of opiate dependence is based on the substitution model in which an alternative to illicit opiates is prescribed to reduce the need to use those drugs.• Methadone is seen as the gold standard of substitute drug for a number of reasons: Desirable properties of methadone as a substitute medication  As effective when taken orally as when injected  Long acting (24-36 hour half life). Allows for daily dosing Relatively non-euphoriant  Little need to increase dose over time (i.e. tolerance) (Seivewright, 2009) Paul Molyneux
    • • Studies that compared methadone to placebo where eventually deemed unethical due to methadone’s clear superiority (see Dole et al. 1969; Newman & Whitehill 1979)• A 2009 Cochrane meta-analysis concluded that: “Methadone is an effective maintenance therapy intervention for the treatment of heroin dependence as it retains patients in treatment and decreases heroin use better than treatments that do not utilise opioid replacement therapy” (Mattick et al. 2009).• Interestingly, the authors also noted that: “It does not show a statistically significant superior effect on criminal activity or mortality” (Mattick et al. 2009). Paul Molyneux
    • Dosing• Donny et al. (2002) have divided methadone dosing into three levels: Level 1 Level 2 Level 3 Low dose Medium dose High dose <60mg 60-100mg >100mg Holds the client, i.e. Reduces cravings Full narcotic stops withdrawals for opiates blockade• In reality, dosing is far more nuanced than this.• Studies have consistently shown that higher doses of methadone (>60mg per day) result in lower levels of heroin use and increased retention in treatment over lower doses of methadone (<60mg per day) (Seivewright 2009). Paul Molyneux
    • Preparations Liquid• The form of methadone most widely used, usually as a 1mg in 1ml mixture.• Other strengths include a 2mg in 5ml linctus (used for terminal cough - unlicensed as substitute medication), and 10mg in 1ml.• Also available in sugar free and colouring free preparations. Paul Molyneux
    • Preparations Cont. Tablet• Prescribing of methadone in tablet form is roundly discouraged in the United Kingdom.• Tablets prove popular with clients as they can be easily diverted and sold illicitly. They command a high market value as they cannot be diluted or adulterated (Preston 2003)• Often used when the carrying of liquid methadone is unfeasible (e.g. holiday prescriptions). Paul Molyneux
    • Preparations Cont. Injectable Ampoules• Considered useful for small minority of clients who have difficulty giving up injecting (needle fixation?).• Generally, clinicians will only prescribe if there is evidence of complete abstinence of street drug use (e.g. clean urine samples). Paul Molyneux
    • Prescription Breakdown 9% Oral Liquid 11% Tablet Injectable Ampoule 80% Paul Strang et al. (1996)
    • Adverse Effects - Serious• Overdose: – This can occur at 40mg for a non-tolerant adult and 10mg or lower for a child (this is why safe storage is vital!!!) – Risk of overdose is exacerbated by other CNS depressant drug use (e.g. alcohol, BNZs)• Polymorphic ventricular tachycardia: – A life-threatening arrhythmia that generally occurs in higher doses. – ECG monitoring is suggested when dose titrated above 100mg (MHRA 2010) Paul Molyneux
    • Adverse Effects - Minor• Constipation• Sweating• Weight gain• Dental problems• Nausea• Amenorrhoea• Depression/lethargy• Reduced sexual desire (Seivewright, 2009) Paul Molyneux
    • Withdrawal• Withdrawal from methadone, though less acutely severe than those of morphine or heroin, are far more prolonged (Rassool 2009).• Withdrawal symptoms usually emerge after 24-36 hours after cessation and can last several weeks. Paul Molyneux
    • Withdrawal Symptoms Nausea & Rhinnorrhea Tremor vomiting (runny nose) Lacrimation (tearing) Withdrawal SymptomsMuscular aches and pains Tachycardia Anxiety Diarrhoea Rassool (2009) Paul Molyneux
    • Question Time Paul Molyneux
    • BibliographyDole V.P., Robinson, J.W., Orraca, J., Towns, E., Searcy, P., Caine, E. (1969) Methadone treatment of randomly selected criminal addicts. New England Journal of Medicine, 280, 1372-5.Donny, E.C, Walsh, S.L., Bigelow, G,.E., Eissenberg, T., Stitzer, M.L. (2002) High- dose methadone produces superior opioid blockade and comparable withdrawal suppression to lower doses in opioid dependent human. Psychopharmacology, 161, 202-12.Hanson, G.R., Venturelli, P.J., Fleckenstein, A.E. (2009) Drugs and Society. 10th ed. Massachusetts: Jones and Bartlett Publishers.Joseph H, Stancliff S, Langrod J (2000). Methadone maintenance treatment: a review of historical and clinical issues. Mt. Sinai J. Med. 67 (5-6), 347–64Newman, R.G., Whitehall, W.B. (1979) Double blind comparison of methadone and placebo maintenance treatments of treatments of narcotic addicts in Hong Kong. Lancet, 2, 485-8. Paul Molyneux
    • BibliographyMattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database of Systematic Reviews 2009, Issue 3.MHRA. (2010). Methadone 1mg/ml Oral Solution. Available: http://www.mhra.gov.uk/home/groups/par/documents/websiteresources /con105829.pdf. Last accessed 23 July 2011.Preston, A. (2003). The Methadone Briefing. Available: http://www.drugtext.org/library/books/methadone/section3.html. Last accessed 24 July 2011.Rassool, G. (2009) Alcohol and drug misuse: a handbook for students and health professionals. Oxon: RoutledgeSeivewright, N. (2009). Community Treatment of Drug Misuse: More Than Methadone. 2nd ed. New York: Cambridge University Press. Paul Molyneux
    • BibliographyStrang, J., Sheridan, J., Barber, N. (1996) Prescribing injectable and oral methadone to opiate addicts: results from the 1995 national postal survey of community pharmacies in England and Wales. British Medical Journal, 313, 270-2. Paul Molyneux
    • This presentation was developed by Paul Molyneux (registered nurse) and has been peer reviewed by Dr D. Butterworth of the Blackburn with Darwen Alcohol and Drug Service. Paul.molyneux@gmw.nhs.uk Paul Molyneux